INTRODUCTION
============

Since the discovery of the role of endothelium on vascular tone regulation at the beginning of 1980s, a countless number of studies have shown the plethora of remarkable functions that this tissue has in vascular physiology. Notably significant advances in understanding the role of endothelium have used human umbilical and placental vessels as experimental models, which is also applied to the knowledge regarding endothelial diversity. The diversity of functions that the endothelium exerts (i.e., regulation of vessel tone, angiogenesis, immune cell adhesion and migration, exchange, and haemostasis) associates with specific "zones" of the vasculature, suggesting that endothelial cells present a phenotypic heterogeneity that supports this functional diversity ([@B5]). From the molecular point of view endothelial cells *in vivo* express several proteins which allow to distinguish between arterial and venous endothelial cells and some of these patterns are preserved *in vitro*, suggesting that long term endothelial physiology is importantly influenced by epigenetic mechanisms ([@B66]; [@B1]).

ORIGINS OF ENDOTHELIAL CELLS
----------------------------

Vasculogenesis is the process by which vessels are formed from mesenchymal-derived hemangioblasts which differentiate into endothelial cells ([@B17]). Current evidence shows that initial stages of vascular development are determined by genetic factors ([@B63]; [@B5]). These processes require the expression of VEGF ([@B82]) and activation of downstream mitogenic effectors ([@B73]; [@B83]). However, the site from which the vascular progenitors for placental and embryo vasculogenesis emerge is still debated. It is accepted that in the embryo vascular progenitors emerge from intra- and extra-embryonic mesodermal tissues ([@B41]), whilst in the placenta they arise from the extra-embryonic mesoderm ([@B12]). However, there is growing evidence for a crucial role of the yolk sac in embryo and placental vascular development ([@B29]). Indeed, using a sodium-calcium exchanger (*Ncx-1*) knockout mice which fails to initiate cardiac contraction [@B65] showed that all the hematopoietic progenitor cells emerge from the yolk sac. The origin of placental endothelial cells could have an important impact on its vascular physiology because arterial-venous identity is early established by environmental cues which could have diverse effects depending on the localization in the embryo.

Growth and consolidation of the placental vascular tree occurs by angiogenesis. In this process single vessels are formed by endothelial precursor cells (EPCs) which differentiate into endothelial cells, and/or proliferate from endothelial cells. These vessels can spread in two ways, (1) non-branching angiogenesis, which implies an increase in the length of the villous vessels, and (2) branching angiogenesis, in which multiple short capillary loops are formed ([@B17]), increasing the vascular surface area. After these processes have taken place, the vessels mature and their structures stabilize. Additional maturation and specialization in the vascular system are influenced by environmental signals, such as blood flow, oxygen tension, oxidative stress, and epigenetic factors ([@B63]; [@B5]). All these factors have been implicated in the development and function of the human placenta ([@B28]; [@B9]; [@B18]). Thus, angiogenesis is a complex process which involves genetic, epigenetic and environmental commands in the development and establishment of the vasculature.

EPIGENETICS OVERVIEW
====================

During the last decade, the study of genome-environment interactions has revealed a plethora of mechanisms that modulate short and long term cellular physiology. These mechanisms involve mainly epigenetic processes which control chromatin accessibility in a gene- and cell-specific manner. Definition of epigenetics is still under debate mainly due to the several molecular mechanisms that it comprises and the heritability of these changes in an organism and its progeny; however, a simple and broad definition considers epigenetic mechanisms as "chromosome-based mechanisms that change the phenotypic plasticity in a cell or organism" ([@B53]; [@B32]).

Epigenetic mechanisms affect chromatin structure and gene expression regulating DNA and histone interactions, and the translation and stability of mRNA. Epigenetic markers such as DNA methylation, histone deacetylation, and other repressive histone post-translational modifications (PTMs) alter the structure of the chromatin, generating regions with a "closed chromatin" conformation. Conversely, DNA demethylation (potentially driven by the oxidation of methylated cytosines and their replacement by base excision repair; [@B50]), ATP-dependent chromatin remodeling, histone acetylation (Ac), and other permissive histone PTMs, convert the closed chromatin into an "open chromatin" conformation allowing binding of transcription factors and the RNA polymerase II (**Figure [1](#F1){ref-type="fig"}**). As an additional epigenetic mechanism, the presence of non-coding RNAs can post-transcriptionally repress gene expression. Detailed reviews of the diverse epigenetic mechanisms and their effects on gene expression are available ([@B48]; [@B52]; [@B90],[@B91]; [@B43]; [@B50]).

![**Epigenetic mechanisms regulating gene expression.** Epigenetic mechanisms control gene expression by increasing (green histones) or limiting chromatin accessibility (red histones). These states result from the equilibrium of modifications on the DNA and histones which reduce (left list) or promote (right list) DNA/histones interactions. Alternatively gene expression is limited by the presence of non-coding RNA. Symbols "!?" denote recently reported mechanisms whose effects are currently under study.](fphar-05-00049-g001){#F1}

From a developmental perspective epigenetic mechanisms allow the generation of diverse cell phenotypes and functions of an organism from a single genome, and respond to a range of environmental fluctuations. This issue is especially evident in organs and tissues whose structure and function are under constant change across lifespan, such as the cardiovascular system ([@B1]). Nonetheless, placental vasculature may also be programmed by epigenetic mechanisms, which are currently under restless research.

EPIGENETICS IN ENDOTHELIAL PHYSIOLOGY AND PATHOPHYSIOLOGY
---------------------------------------------------------

Vascular development, endothelial differentiation and function require a fine epigenetic tuning (**Table [1](#T1){ref-type="table"}**). Initial steps of vascular development in the embryo seem to be influenced by both genetic and environmental stimuli which drive the emergence of two different populations of endothelial cells ([@B5]). Differentiation of embryonic stem cells and EPCs into endothelial cells requires the participation of histone deacetylases (HDAC), lysine demethylases (KDM) and reduced DNA methylation in the promoter region of endothelial-specific genes ([@B79]; [@B97]; [@B58]; [@B6]; [@B70]). Conversely, differentiated endothelial cells can be reprogramed to a pseudo-embryonic stem cell phenotype increasing the DNA methylation status of endothelial-specific genes ([@B57]). In endothelial cells, activating histone PTM, such as acetylation of H3 and H4 and methylation of H3K4, control the basal expression of vWF ([@B74]), NOTCH4 ([@B94]), VEGF receptor 1 ([@B21]), endomucin ([@B44]), and eNOS ([@B25]; [@B31]).

###### 

Effect of DNA methylation and histone post-translational modifications (PTMs) on endothelial cell physiology.

  Mechanism             Process                                                                                                                                                  Reference
  --------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------
  DNA methylation       *In vitro* and *in vivo* progenitor endothelial cells differentiatio Activation of tissue-specific genes Ischemia-induced neo-vascularization            [@B13], [@B58], [@B70], [@B77]
  Histone acetylation   Hypoxia-, VEGF- and shear stress- induced angiogenesis VEGF-induced progenitor endothelial cells differentiation Basal endothelial cell-specific genes   [@B47], [@B19], [@B78], [@B74], [@B36], [@B97], [@B94]
  Other histone PTMs    Progenitor endothelial cells differentiation Hypoxia induced eNOS down-regulation                                                                        [@B70], [@B27]

On the other hand, HDAC activity is required for an adequate vascular integrity ([@B14]) preventing short term endothelial proliferation and angiogenesis ([@B33]; [@B40]), whilst calmodulin-lysine *N*-methyltransferase (KMT) activity has the opposite effect ([@B20]). However, long term HDAC activity promotes angiogenesis in response to VEGF ([@B19]) and hypoxia ([@B47]) increasing the expression of VEGF ([@B80]) and eNOS ([@B78]). Similarly, HDAC activity is increased in response to shear stress ([@B35]) improving cell survival ([@B96]) and eNOS expression ([@B93]). Noteworthy, the epigenetic regulation of NOS3 gene has been extensively studied in endothelial and non-endothelial cells, showing that endothelial cells have a distinctive pattern of DNA methylation and histone PTMs ([@B24]). [@B26] reported that the decreased expression of eNOS in HUVEC exposed to acute hypoxia is controlled by the overexpression of a natural *cis*-antisense non-coding RNA called sONE, and changes in histone PTMs which occur specifically at the eNOS promoter ([@B27]). Additionally, abrogation of NOS3 promoter DNA methylation increases basal eNOS mRNA expression *in vitro*, and protects against hind-limb ischemic injury *in vivo* ([@B77]).

Several studies show that epigenetic mechanisms participate in the increased risk of developing vascular diseases. In humans, endothelial cells from atherosclerotic plaques have decreased levels of estrogen receptor β along with increased DNA methylation at the promoter region of this gene, compared with those from non-atherosclerotic plaque regions ([@B46]). Deficiency of a specific KDM, lysine-specific demethylase-1 (LSD1, KDM1a), associates with decreased expression of eNOS and NO-dependent vasodilation, as well as, salt sensitive hypertension ([@B76]). In newborn rats with persistent pulmonary hypertension, the increased expression of eNOS mRNA is accompanied by augmented levels of acetylated H3 and H4 in the NOS3 gene promoter ([@B95]). Alternatively, cultured endothelial cells exposed to elevated levels of homocysteine, which relates with increased cardiovascular risk, present decreased proliferation and increased levels of oxidative stress. In both cases homocysteine acts inducing specific hypomethylation of the gene promoters for the cell cycle regulator cyclin A ([@B38]) and the pro-oxidant protein p66shc ([@B45]). Additionally, high glucose-induced endothelial dysfunction requires the participation of HAT ([@B15]) and KMT ([@B23]), generating important epigenomic changes ([@B75]), which can persist several days after the exposure to the noxa ([@B23]).

Notably, vascular physiology is also influenced by epigenetic mechanisms occurring in smooth muscle cells (SMCs). Development of vascular dysfunction is accompanied by changes in SMC phenotype, which shift from a "contractile" to a "synthetic" and "pro-inflammatory" phenotype with long term consequences in the contractile properties of vessels ([@B72]; [@B71]). Increasing data shows that this "phenotypic switching" requires the participation of epigenetic mechanisms which establish an altered SMC function ([@B2]).

PHENOTYPIC AND EPIGENETIC DIVERSITY IN THE UMBILICO-PLACENTAL ENDOTHELIUM
=========================================================================

Pioneer studies by [@B60] demonstrated that micro- and macrovascular umbilico-placental endothelium present different immunoreactivity to diverse molecular markers for endothelial cells, suggesting the presence of a phenotypic endothelial diversity in the placenta. Additional evidence from cultured human endothelial cells isolated from the placental microcirculation (PLEC) and the umbilical vein (HUVEC) show that microvascular endothelial cells express higher levels of vascular mediators (angiotensin II, endothelin, and thromboxane; [@B59]). Also a differential pattern of homeobox genes ([@B69], [@B68]) and higher cholesterol transport capacity ([@B85]) in PLEC compared to HUVEC has been shown.

Notably, studies on endothelial cells from arteries and veins have revealed important differences between arterial and venous cells at the same vascular level. In fact the higher mitogenic response observed in PLEC ([@B59]) may reflect the combination of a high response to VEGF present in arterial PLEC (PLAEC) and to PIGF in venous endothelial cells (PLVEC; [@B61]). A transcriptomic analysis between PLAEC and PLVEC showed that they have differential expression of more than 3,000 genes ([@B61]). Similarly there is a differential expression of eNOS, a key vascular gene, between micro- and macrovascular, and venous and arterial endothelium ([@B3]; [@B56]) being more homogenous at the arterial side ([@B3]). This opens the queries about the differences initially reported between micro- and macrovascular endothelium reflecting an endothelial diversity between large and small vessels, and whether they include variances between arteries and veins.

Several studies comparing simultaneously umbilical arterial (HUAEC) and venous (HUVEC) endothelium support the concept that these cells are not a homogenous population, and the necessity of clarifying the precise source of cells when the term "macrovasculature" is used. A general characterization shows that there is a different profile of phospholipids with higher levels of arachidonic acid-related species and heterogeneous expression pattern of selenoproteins ([@B67]) in HUAEC compared to HUVEC ([@B87]). Alongside the classical molecular markers for arterial endothelium, cultured HUAEC express higher levels of PAI 1 ([@B30]), Cx40 ([@B88]), 17β-HSD2 ([@B84]), and VCAM-1 ([@B22]); and lower levels of von Willebrand Factor ([@B81]) and estrogen receptors beta (ERβ; [@B84]) compared with HUVEC. On the other hand expressions of pro-constrictive mediators such as angiotensin converting enzyme ([@B37]) and ET-1 ([@B22]) are different in HUVEC relative to HUAEC. Furthermore, expression and activity of eNOS are higher in freshly isolated HUVEC than HUAEC ([@B3]) and this expression pattern is also observed in cells cultured up to third passage ([@B56]). Whether these differences reflects the physiology of umbilical (and potentially placental) arteries and veins, and how they are preserved *in vitro* need further examination. Two recent reports show that the differential gene expression between HUAEC and HUVEC is partially controlled by specific transcription factors. Overexpression of the venous-specific nuclear receptor COUP-TFII in HUAEC decreases the expression of arterial markers (i.e., Hey2, EphrinB2 and NICD4), and its down-regulation in HUVEC increases the expression of arterial markers such as VEGF-A, Dll and EphrinB2 ([@B51]). Moreover, *in vitro* simultaneous overexpression of eight arterial-specific transcription factors turns the HUVEC transcriptome into a HUAEC-like pattern ([@B4]).

Therefore, the phenotypic diversity in the umbilico-placental circulation is apparently commanded, at least in part, by an equivalent diversity in epigenetic mechanisms.

ENDOTHELIAL DIVERSITY AND ANGIOGENESIS
--------------------------------------

In terms of angiogenesis, microvascular endothelial cells present a higher mitogenic response to VEGF, PIGF ([@B59]; [@B61]), and prokineticin 1 ([@B8]) compared with HUVEC, along with an increased expression of pro-angiogenic HOX genes (i.e., TLX1, TLX2, and PHOX1; [@B68]). These data are in agreement with the notion that placental angiogenic capacity is augmented in microvascular vessels compared to endothelial cells from larger vessels. However, it is also possible to find significant differences in the angiogenic response in endothelial cells from umbilical arteries and veins. *In vivo* VEGFR3, which is commonly expressed in lymphatic endothelium or during active angiogenesis ([@B49]), is absent in HUAEC but expressed in HUVEC ([@B89]). Moreover *in vitro* chemotaxis induced by VEGFA or FGF2 is higher in HUVEC compared to HUAEC ([@B7]), and netrin-1 prevents the VEGF-induced migration in HUAEC without effect on HUVEC ([@B64]). Further studies are needed to address the effects and the role on placental physiology of this increased angiogenic response observed in HUVEC.

ENDOTHELIAL DIVERSITY IN RESPONSE TO STRESS
-------------------------------------------

Placental vascular and endothelial physiology, similar to adult vasculature, are importantly influenced by stimuli such as altered shear stress and oxygen levels whose effects are apparently different between arteries and veins. Normally arterial endothelium is exposed to higher shear stress and therefore it is plausible to predict a stronger response to increasing stress. In fact pulsatile shear stress increases the expression of arterial markers (i.e., Hey1, Hey1, and ephrinB2) in HUAEC but decreases the expression of venous markers (COUP-TFII) in HUVEC ([@B11]). Laminar shear stress have similar effects on the expression of arterial-venous markers in these cells, and increases the levels of *S*-nitrosylated proteins ([@B34]) endothelin-1, VCAM, and vWF ([@B22]) in HUAEC compared to HUVEC. Whether these differences are observed in microvascular endothelial cells remains to be determined.

Some evidence regarding the effects of low oxygen levels on endothelial function in placental large and small vessels, as well as arteries and veins, show a differential vascular response to hypoxia throughout the placenta ([@B55], [@B56]). On the other hand placental endothelium is importantly exposed to low oxygen levels and oxidative stress which are negative regulator of placental angiogenesis ([@B10]). A reduction in oxygen levels from 21 to 12% O~2~decreases placental venous microvascular endothelial cells viability with no effect on their arterial counterparts ([@B62]), and PLAEC exposed to 3% O~2~ show an increased mitogenic response to VEGFA and FGF2 compared to cells cultured at 21% O~2~ ([@B92]). This higher response to VEGFA and FGF2 is also observed in HUAEC exposed to physiological levels of oxygen (3--5% O~2~; [@B39]). Additionally, hypoxia (1% O~2~) increases the expression of the pro-angiogenic factor protease-activated receptor 2 in HUVEC and this effect is higher in HUAEC ([@B86]).

Altogether these data show that venous-arterial endothelial phenotypic diversity occurs among umbilical and placental vessels (**Figure [2](#F2){ref-type="fig"}**). Further studies should include control comparison between arterial and venous endothelial cells from the same branching level to rule out potential differences attributable to arteries and veins rather than micro- and macrovascular vessels. It is worth to note that most of the differences occurring among these cells types could be reverted by genetic manipulation. However, its persistence *in vitro* suggests that additional mechanisms controlling gene expression should be operating, arguing for a crucial role for epigenetics in this process.

![**Phenotypic diversity in the umbilico-placental endothelium.** Umbilical (macrovascular) and placental (microvascular) endothelial cells present a phenotypic diversity characterized by a differential response to angiogenic factors and gene expression of key endothelial genes. In the figure thickness of the triangle denotes deferential relative expression (or response) regarding arteries or veins at each level. Square text box includes common traits between macro- and micro-vascular arterial or venous endothelial cells. 11β-HSD1, 11β-hydroxysteroid dehydrogenase 1; 17β-HSD2, 17β hydroxysteroid dehydrogenase 2; ARG2, arginase-2 gene; Cx40, conexin-40; eNOS, endothelial nitric oxide synthase; ET-1, endothelin-1; KDR, vascular endothelial growth factor (VEGF) receptor 2; NOS3, eNOS gene; PAI 1, plasminogen activator inhibitor-1; PlGF, placental growth factor; VCAM-1, vascular cell adhesion molecule 1.](fphar-05-00049-g002){#F2}

EPIGENETIC AND PLACENTAL ENDOTHELIAL DIVERSITY
----------------------------------------------

Compelling evidence shows the fundamental role of epigenetics controlling the endothelial-specific gene expression, however, the next frontier is to determine how epigenetic mechanisms influence the endothelial functional diversity. Two recent reports studying placental and umbilical endothelial cells suggest the presence of significant differences in the DNA methylation of gene promoters which could be responsible for the differential gene expression present in these cells.

A comparison of the genome-wide DNA methylation profile in PLAEC and PLVEC show that venous endothelial cells present lower levels of global methylation compared to PLAEC ([@B42]) which could reflect the immature phenotype of PLVEC ([@B61]). Further analysis show the presence of several genes which are differentially methylated between PLAEC and PLVEC, and some of them present an inverse correlation between the level of methylation and the gene expression. Notably those genes are considered endothelial markers and play a key role in vascular physiology, such as eNOS, vWF, Conexin40, VEGFR1, VEGFC, and angiopiotein-1. However, there are endothelial genes whose promoters do not present any correlation between methylation levels and gene expression, such as VEGFR2, Hey2, NOTCH, EphB2, and EphB4 ([@B42]).

Conversely, the comparison of DNA methylation status of NOS3 (eNOS) and ARG2 (arginase-2) promoters by pyrosequencing in HUAEC, PLAEC and HUVEC, suggest the presence of site-specific differences between these cells. Methylation status at NOS3 promoter in umbilical and placental endothelial cells showed differences in three specific CpG between arterial and venous endothelial cells ([@B54]). Two of these differentially methylated CpGs correspond to the reported hypoxia response element (-5369 and -5375; [@B16]) which regulates the response to hypoxia and show lower methylation levels in PLAEC and HUAEC compared to HUVEC. Whether this variation participates in the differential regulation of eNOS expression in response to hypoxia that has been reported between HUAEC and HUVEC ([@B56]) needs to be addressed. An additional differentially methylated CpG is located at -352 from the transcription starting site, showing a higher methylation pattern in arterial relative to venous cells. Moreover the methylation status at this CpG suggests an inverse correlation between DNA methylation and eNOS expression, which is higher in HUVEC (lower methylation levels) compared to HUAEC ([@B56], [@B54]). It is also reported that CpG -352 is differentially methylated between HUVEC and human dermal microvascular endothelial cells ([@B13]), having the later a methylation status comparable to that found in HUAEC and PLAEC, which suggest that CpG -352 might play a role in the differential regulation of basal eNOS expression in arterial and venous endothelial cells. [@B54] compared the NOS3 promoter DNA methylation status between control and endothelial cells isolated from pregnancies with intrauterine growth restriction (IUGR). Remarkably changes in DNA methylation in IUGR cells are restricted to those CpGs that are differentially methylated in normal endothelial cells. In fact, IUGR HUAEC and PLAEC present similar changes at CpGs -5375 (increased methylation) and -352 (decreased methylation) compared with normal cells, and these methylation levels are comparable to that find in normal HUVEC. Conversely, changes in the DNA methylation status of IUGR HUVEC where at CpGs -5369 (decreased methylation) and -352 (increased methylation), and they are comparable to those find in normal HUAEC and PLAEC. The methylation levels at CpG -352 in IUGR HUAEC and HUVEC are also related with the levels of mRNA for eNOS ([@B54]), reinforcing the potential importance of CpG -352 in the regulation of basal eNOS expression. Finally analysis of methylation status of ARG2 promoter in HUAEC, PLAEC, and HUVEC show a single difference between PLAEC and HUVEC, however, it is still unknown if there is a correlation with arginase-2 expression and activity.

DNA methylation is one of the main epigenetic mechanisms that controls long term gene expression, showing a high reproducibility after every cellular replication and this characteristic is driven by the activity of DNA methyltransferase-1 (DNMT1). In IUGR HUAEC and HUVEC DNMT1 silencing shows a differential effect, reducing and increasing basal eNOS expression, respectively ([@B54]). Silencing of DNMT1 restores to normal eNOS mRNA levels in IUGR HUAEC and HUVEC, and this effect is not observed on arginase-2 expression where it further increases its expression in IUGR HUVEC, without any effect in IUGR HUAEC ([@B54]). This suggests that DNA methylation ([@B38]; [@B6]; [@B45]) and other epigenetic mechanisms ([@B47]; [@B19]; [@B27]) control gene expression in endothelial cells in a gene-specific manner.

Although the studies in PLAEC and PLVEC ([@B42]), and in HUAEC and HUVEC ([@B54]) used two different approaches to analyze the DNA methylation patterns, there are some similarities in the outcomes. First, both studies show that methylation status of NOS3 proximal promoter inversely correlates with the levels of mRNA for eNOS, and this occurs in cells exposed for several days to culture conditions. Second, PLAEC and PLVEC show differential levels arginase-2 expression without differences in the DNA methylation in ARG2 promoter, whilst in control and IUGR HUAEC differences in DNA methylation are not associated to difference in arginase-2 expression. Finally, DNMT1 silencing in IUGR cells normalize eNOS expression but not arginase-2 expression.

CONCLUSION
==========

Altogether these seminal data show that epigenetic mechanisms could be responsible for the phenotypic diversity of endothelial cells in the umbilico-placental unit, and these mechanisms would be operating in a cell- and gene-specific manner. The current research on the area is offering novel data about potential mechanisms but still further studies are required to have a comprehensive picture of the additional epigenetic mechanisms controlling the gene expression in physiological and pathophysiological conditions and its consequences in umbilico-placental functions.
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